PMD Psychemedics: Multiplikator Forward P/S
The drug hair analysis market has reached maturity, forcing Psychemedics to expand into the educational sector. An impeccable reputation in occupational health and safety establishes the company as an industry benchmark. The forward P/S multiple reflects market revenue expectations, and its current level is 0.80. Synergy with government agencies and corporations through joint testing projects strengthens the brand's position.
Ringkesan rincian data analitis Psychemedics Inc (PMD)
- rega saham lan target rega konsensus:
- data kapitalisasi saham perusahaan:
- statistik nilai buku emiten:
- data tingkat utang lan likuiditas finansial:
Utang marang Ekuitas Psychemedics|PMD - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal Psychemedics|PMD - Utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku Psychemedics Inc|PMD - Tanggungan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Psychemedics|Rasio cepet psychemedics.com
- rincian asil keuangan lan kelipatan valuasi:
PMD - Penghasilan resik|Bathi sing dikarepake Psychemedics|PMD - Periode bali modal bisnis|Rega marang bathi mangsa ngarep Psychemedics Corp|PMD - Rasio kapitalisasi marang bathi lan wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Psychemedics Inc|PMD - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben saham (EPS TTM) Psychemedics|PMD - Bathi saben saham sajrone 12 wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan psychemedics.com|PMD - Wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi kanggo taun ngarep Psychemedics
- statistik dodolan lan pendapatan perusahaan:
Analisis wiwitan perusahaan:Psychemedics Corporation PMD
The forward P/S ratio determines the relationship between market capitalization and expected sales volume, allowing for an assessment of the asset's overvaluation relative to future cash flows. The current value of 0.80 based on the forward P/S valuation reflects the resilience of Psychemedics (PMD) to cost inflation, which is supported by inelastic demand for mandatory compliance testing and stable free cash flow generation.
Analisis pesaing Psychemedics
Agilent - Multiplikator forward rega marang pendapatan|Quest Diagnostics Inc. (DGX) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Illumina Corp - Multiplikator Forward P/S|Exact Sciences Inc. (EXAS) - Multiplikator forward rega marang pendapatan|RVTY: Multiplikator Forward P/S|bio-rad.com - Rega forward marang dodolan|NNNN (Anbio) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Sotera Health Corp SHC|Rasio rega marang prakiraan pendapatan QuidelOrtho Corp (QDEL)|Multiplikator forward rega marang pendapatan OPKO Health Corp. OPK|Multiplikator Forward P/S CDNA (CareDx, Inc)|maravai.com (MRVI) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Fulgent Genetics - Multiplikator Forward P/S|LAB (Standard BioTools Inc) - Kapitalisasi marang prakiraan pendapatan|CTKB: Multiplikator Forward P/S|OSUR - Rasio kapitalisasi marang dodolan sing dikarepake|XGN (Exagen Inc) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan mdxhealth.com (MDXH)|Rasio rega marang prakiraan pendapatan Lucid Diagnostics (LUCD)|Rasio kapitalisasi marang dodolan sing dikarepake prenetics.com|Rasio rega marang prakiraan pendapatan Insight Molecular Diagnostics Inc IMDX|TRIB (Trinity Biotech PLC) - Rega mangsa ngarep marang pendapatan|PRPH - Rasio rega marang prakiraan pendapatan|ainos.com (AIMD) - Multiplikator forward rega marang pendapatan|CODX: Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan HSCS|Rasio rega marang prakiraan pendapatan Biomerica, Inc|Multiplikator forward rega marang pendapatan Cardio Diagnostics Holdings, Inc. (CDIO)|Multiplikator Forward P/S ONCO|VRAX - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Multiplikator Forward P/S BJDX (Bluejay Diagnostics, Inc.)|AWH: Kapitalisasi marang prakiraan pendapatan|Accelerate Diagnostics, Inc - Multiplikator Forward P/S|CNTG - Multiplikator Forward P/S|enzo.com (ENZ) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan FRES|GENE (Genetic Technologies Ltd) - Multiplikator Forward P/S|Multiplikator Forward P/S 23andMe Holding Co
